News & Media
Read about our latest news and initiatives, and find more information about Acadia.
Featured Perspectives
Latest News Releases
About Acadia
Acadia is advancing breakthroughs in neuroscience to elevate life. For 30 years, we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapies for hallucinations and delusions associated with Parkinson’s disease psychosis and for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Alzheimer’s disease psychosis and neuropsychiatric symptoms in central nervous system disorders.
Assets & Materials
Therapeutic Area Fact Sheets
Contacts
Media

Investors
